Murakami, Hitoshi
Yamada, Takanobu
Taguri, Masataka
Hasegawa, Shinichi
Yamanaka, Takeharu
Rino, Yasushi
Mushiake, Hiroyuki
Oshima, Takashi
Matsukawa, Hiroshi
Tani, Kazuyuki
Suzuki, Yoshihiro
Ozawa, Yukihiro
Tanabe, Hiroyasu
Osaragi, Tomohiko
Sato, Tsutomu
Tamagawa, Hiroshi
Yukawa, Norio
Yoshikawa, Takaki
Imada, Toshio
Masuda, Munetaka
Yamamoto, Yuji
Article History
Accepted: 24 January 2021
First Online: 10 February 2021
Compliance with ethical standards
:
: Dr. Yamada reports personal fees from ONO Pharmaceutical and personal fees from Bristol-Myers Squibb, outside the submitted work. Dr. Yamanaka reports grants and personal fees from Takeda, grants and personal fees from Chugai, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Taiho, grants and personal fees from Daiichi-Sankyo, grants from Ono, grants and personal fees from Bayer, grants from Merck Serono, grants from Astellas, grants from Eli Lilly, personal fees from Pfizer, personal fees from Sysmex, personal fees from Huya Biosciences, and personal fees from Gilead Sciences, outside the submitted work. Dr. Rino reports personal fees from Taiho pharmaceutical, personal fees from Abbott, personal fees from Asahi Kasei, personal fees from Daiichi-Sankyo, personal fees from Tsumura & Co, personal fees from Covidien, personal fees from Zeria pharmaceutical, personal fees from EA Pharma, personal fees from Johnson and Johnson, personal fees from Otsuka, other from Lilly, other from Bristol-Myers Squibb, other from Daiichi-Sankyo, other from Johnson and Johnson, other from Otsuka, and other from Taiho pharmaceutical, outside the submitted work. Dr. Oshima reports grants from Taiho pharmaceutical Co., Ltd, grants from Chugai pharmaceutical Co., Ltd, grants from Ono pharmaceutical Co., Ltd, grants from Daiichi-Sankyo pharmaceutical, grants from Nippon Kayaku Co., Ltd, grants from Eli Lilly Japan K. K., personal fees from Nippon Kayaku Co., Ltd, personal fees from Ono pharmaceutical Co., Ltd, personal fees from Bristol-Myers Squibb K. K., personal fees from Taiho pharmaceutical Co., Ltd, personal fees from Chugai pharmaceutical Co., Ltd, and personal fees from Eli Lilly Japan K. K., outside the submitted work. Dr. Yoshikawa reports personal fees from MSD, personal fees from BMS, personal fees from ONO, personal fees from Taiho, personal fees from Chugai, personal fees from Nihon Kayaku, grants and personal fees from Lilly, personal fees from Pfizer, personal fees from TERUMO, personal fees from Johnson and Johnson, and personal fees from Covidien, outside the submitted work; All the remaining authors have no conflicts of interest to declare.
: This trial was registered with the University Hospital Medical Information Network Clinical Trials Registry (ExternalRef removed: UMIN000005421) and was approved by the ethical review boards of the participating institutions. All patients provided informed consent before enrollment.